ESTRO 2024 - Abstract Book

S1760

Clinical - Lung

ESTRO 2024

Most patients experienced some type of G1-G2 acute or chronic toxicities, with the most common type being pneumonitis (38.2% and 47.1%, respectively). Acute G3 toxicity developed in one patient (2.9%) and no one developed chronic G3 toxicity..No grade 4 or 5 toxicity was observed. The number of respiratory infections was collected during the first year following SBRT. Forty-seven percent (16/34 patients) of the sample had at least one respiratory infection. Of these 16 patients, seven of them (43.75%) presented 2 or more infections in the first year post-SBRT. A total of 26 episodes were counted, of which 42.3% required hospital treatment >24 hours. No deaths related to respiratory infections occurred, nor was intensive care unit treatment or invasive ventilation required. The median time to onset of the first respiratory infection was 91 days (IQR 76 - 116).

Conclusion:

Lung SBRT in patients with poor pulmonary function may be effective with acceptable toxicity. The decision to recommend SBRT should be made after a thorough evaluation of the potential risks and benefits, particularly for patients with a favorable medium-term prognosis resulting from their underlying medical condition

Keywords: Stereotactic Body Radiotherapy, COPD, Toxicity

References:

Guckenberger M, Kestin LL, Hope AJ, et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer. J Thorac Oncol. 2012;7(3):542-51.

Palma D, Lagerwaard F, Rodrigues G, Haasbeek C and Senan S: Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 82: 1149-1156, 2012.